卓正医疗于1月29日至2月3日招股 预计2月6日上市

Core Viewpoint - 卓正医疗 is set to launch an IPO from January 29 to February 3, 2026, aiming to raise approximately HKD 2.19 billion through the global offering of 4.75 million shares, targeting the high-end medical service market in China [1][2][4]. Group 1: IPO Details - The company plans to offer 4.75 million shares, with 10% allocated for Hong Kong and 90% for international investors, plus a 15% over-allotment option [1][3]. - The expected price range for the shares is HKD 57.7 to 66.6, with trading anticipated to begin on February 6, 2026 [1][3]. Group 2: Target Market and Strategy - 卓正医疗 focuses on the high-end medical service market, targeting affluent individuals who prefer personalized care [1][3]. - The company has established cornerstone investment agreements with Health Vision, 金域医学检验, 明略科技, and Galaxy Dynasty, securing commitments of USD 11.64 million for share purchases [1][3]. Group 3: Use of Proceeds - The estimated net proceeds of approximately HKD 2.19 billion will be allocated as follows: - 35% for developing a talent pool for medical AI applications and enhancing IT systems [2][4]. - 30% for upgrading existing medical facilities and establishing new ones to broaden patient reach [2][4]. - 25% for acquiring well-performing medical institutions in first-tier and new first-tier cities [2][4]. - 10% for working capital and general corporate purposes [2][4].